Healthcare Equipment and Supplies
Company Overview of Avinger, Inc.
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe. The company develops lumivascular platform, which integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. Its lumivascular products include the Lightbox imaging console and Ocelot family of catheters, which are designed to penetrate total arterial blockages, known as chronic total occlusions (CTOs). The company is also developing Pantheris...
400 Chesapeake Drive
Redwood City, CA 94063
Founded in 2007
Key Executives for Avinger, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $375.0K
Founder and Executive Chairman
Total Annual Compensation: $335.0K
Chief Financial Officer and Chief Business Officer
Total Annual Compensation: $275.0K
Compensation as of Fiscal Year 2015.
Avinger, Inc. Key Developments
Avinger, Inc. Provides Revenue Guidance for the Full Year of 2016
Jan 9 17
Avinger, Inc. provided revenue guidance for the full year of 2016. For the period, the company expects revenue to be of USD 19.2 million, up 79% from 2015.
Avinger, Inc. Provides Earnings Guidance for the Fourth Quarter Ended December 31, 2016
Jan 6 17
Avinger, Inc. provided earnings guidance for the fourth quarter ended December 31, 2016. The company announced that based on preliminary unaudited financial results, it expects total revenue of approximately $4.7 million for the fourth quarter ended December 31, 2016, an increase of 62% from the fourth quarter of 2015 and a decrease of 11% from the third quarter of 2016.
Avinger, Inc. Announces New FDA Clearance for Lumivascular Imaging Console, Enabling Vessel Measurement Via Touchscreen
Dec 22 16
Avinger, Inc. announced that the company has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Lightbox L250 imaging console. With this new FDA clearance, the Lightbox L250 now provides detailed measurement of vessels with a few simple taps to a touch screen, helping further improve visualization inside the vessel before, during, and after Pantheris™ Lumivascular atherectomy procedures for the treatment of PAD. In addition, this enhanced technology allows the clinician to create borders and measurements in seconds to determine the area of any vessel feature, automatically generate minimum and maximum diameters within a given area, and generate vessel size measurements for reference vessel sizing to facilitate adjunctive therapies. Users can easily add and move reference points for even greater control. Atherectomy is a minimally invasive treatment for PAD in which a catheter-based device is used to remove plaque from a blood vessel. Lumivascular technology allows physicians, for the first time ever, to see from inside the artery during a directional atherectomy procedure by using an imaging modality called optical coherence tomography, or OCT, which is displayed on the Lightbox console. In the past, physicians have had to rely solely on X-ray as well as tactile feedback to guide their tools while treating complicated arterial disease. With the Lumivascular approach, physicians can more accurately navigate their devices and treat PAD lesions, the real time OCT images generated from inside the artery, without exposing healthcare workers and patients to the negative effects of ionizing radiation. The new software will be made available to all existing L250 users at no cost and will be incorporated in all future Lightbox products as part of the standard software packages.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|